Group 1: Channel Optimization and Sales Outlook - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining strong offline sales efforts [3] Group 2: New Product Planning - The company has a well-prepared new product plan for 2026, covering various product forms including dressings, masks, lotions, creams, and serums, with actual launches to be confirmed later [3] Group 3: Non-Patch Product Revenue Trends - Since the establishment of the Shanghai R&D center, the company has increased its focus on non-patch products, leading to a rising revenue share from these products [3] Group 4: OTC Channel Development - The current coverage of the OTC channel is relatively low, indicating significant expansion potential; the company plans to increase personnel in this area to improve pharmacy coverage [3] Group 5: Sales Performance and Promotions - Sales during the 38 Festival are meeting expectations, with a focus on daily sales complemented by promotional activities to enhance overall performance [3] Group 6: Product Development Progress - Clinical trials for the recombinant type III humanized collagen freeze-dried fibers have been completed, with submission materials being prepared; other products are at various stages of clinical trials [3] Group 7: Shareholder and Acquisition Plans - The chairman has no current plans to reduce his shareholding, and while the company is monitoring potential acquisition targets, there are no suitable candidates at this time [3] Group 8: Dividend Considerations - The dividend proposal for the fiscal year 2025 has not yet been determined, and stakeholders are encouraged to stay updated [4]

Group 1: Sales and Market Strategy - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining offline sales efforts [3] - The company has increased personnel in the OTC channel to improve pharmacy coverage, indicating significant growth potential in this area [3] Group 2: Product Development and Innovation - The company has a well-prepared product plan for 2026, including various new product forms such as dressings, masks, lotions, creams, and serums [3] - Since the establishment of the Shanghai R&D center, the revenue share of non-patch products has been increasing due to ongoing R&D efforts [3] - Progress on three types of medical devices includes completion of clinical trials for recombinant type III humanized collagen freeze-dried fibers and initiation of clinical trials for other products [3] Group 3: Financial and Corporate Governance - The chairman has no plans to reduce his shareholding in the company, ensuring stability in corporate governance [3] - The dividend plan for the fiscal year 2025 has not yet been determined, pending further developments [4] - The company is monitoring potential acquisition projects but currently has no suitable targets [3]

Group 1: Sales and Marketing Strategies - The company is actively promoting its brand and products ahead of the International Women's Day sales event, aiming for strong sales performance [2] - The company plans to launch new products across various formats, including water, lotion, cream, and essence, in addition to upgrading existing products [2] Group 2: E-commerce Operations - The company has established e-commerce teams in Harbin, Shanghai, and Hangzhou, with specific teams focusing on different platforms like Douyin and Tmall [3] - The profitability of Tmall and Douyin will be assessed after the annual report, but both platforms have shown rapid growth and alignment with company expectations [3] Group 3: Product Development and Medical Devices - The company continues to develop medical devices, focusing on both Class II and Class III products, leveraging a collaborative R&D model [3] - The company aims to enhance its medical device product matrix to improve profitability [3] Group 4: Inventory and Production Management - The company follows a sales-driven production principle to manage inventory effectively, minimizing operational costs and market risks [4] - There is no significant risk of inventory backlog due to the company's efficient production planning [4] Group 5: Future Outlook and Corporate Governance - The company has plans for stock incentives, but the timing and implementation remain uncertain [4] - The chairman currently has no plans to reduce his shareholding in the company [4]

Core Viewpoint - The company, Fuhua (301371), is making progress in optimizing its offline channels, which aligns with its expectations, particularly in sales channel and retail terminal optimization [1] Group 1: Channel Optimization - The company is enhancing cooperation with service-oriented distributors through a dual approach of "strong regulation + strong optimization" to strengthen control over the offline market [1] - The focus of the strong regulation is on the meticulous management of inventory levels at agents and retail terminals to avoid stockpiling risks, while ensuring a stable pricing order through comprehensive and continuous dynamic monitoring of the pricing system across all channels [1] - The optimization aspect emphasizes the careful selection of strategic partners among agents and retail terminals, transitioning the channel model from traditional distribution to value-driven sales [1] Group 2: Future Strategies - The company aims to provide more professional and comprehensive product and service support to its partners and end consumers as part of its channel transformation strategy [1]

Core Viewpoint - The company has achieved preliminary success in optimizing its offline channels, focusing on sales channel and retail terminal improvements, with financial feedback showing some lag [2] Group 1: Channel Optimization - The company is enhancing cooperation with service-oriented distributors through a dual approach of "strong regulation + strong optimization" to strengthen market control [2] - The focus is on meticulous management of inventory levels at both distributors and retail terminals to avoid excess stock risks, alongside comprehensive and ongoing dynamic regulation of the pricing system across all channels to maintain price order stability [2] - The strategy includes careful selection of strategic partners among distributors and retail terminals, transitioning the channel model from traditional distribution to value-driven sales [2] Group 2: Short-term Impact and Future Development - The short-term impact of the offline adjustments on performance is manageable, serving as a foundational project for the company's future high-quality development [2]

Product Launch and Development - In November and December 2025, the company launched a total of 18 new products, with 9 in medical devices and 9 in cosmetics [1] - The company has a clinical-stage medical device, "Recombinant Type III Humanized Collagen Dressing," and is preparing for clinical trials for other collagen-based products [2] Financial Performance and Sales Strategy - The company is currently finalizing its financial results for 2025, with sales data impacted by adjustments in offline sales channels [2] - The transition from traditional distribution to value-driven sales models is expected to improve long-term health in offline business [2] Margin and Cost Management - The company is experiencing pressure on profit margins due to high online sales costs and adjustments in offline sales channels [4] - The fluctuation in gross margin is attributed to increased competition and changes in product mix, with plans for optimization in production, pricing, and supply chain management [2] Channel Optimization and Inventory Management - The company is optimizing its offline channels, focusing on better inventory management and strategic partnerships with service-oriented distributors [4] - Current adjustments in offline channels are expected to have manageable impacts on performance, laying the groundwork for future growth [4] Future Plans and Incentives - The company expresses a strong intention to implement an equity incentive plan as the management team evolves [4]

Core Viewpoint - Watsons is restarting its dual listing plan in Hong Kong and the UK after 11 years, aiming to raise up to $2 billion, with an expected valuation of $30 billion, leveraging the recovery of the Hong Kong stock market for transformation [1] Group 1: Listing Plan Details - The IPO is planned for the first half of 2026, with a maximum fundraising target of $2 billion (approximately 14.213 billion RMB) [1] - This is not Watsons' first attempt at listing; a previous plan in late 2013 was shelved due to market conditions and other factors [2] - The current IPO could become one of the largest consumer retail IPOs in Hong Kong in recent years [2] Group 2: Market Context - The revival of the listing plan is closely linked to the recovery of the Hong Kong stock market, with new stock financing in Hong Kong reaching HKD 216 billion (approximately 197.23 billion RMB) in the first ten months of 2025, more than doubling from the previous year [3] - The Hang Seng Index has seen a year-to-date increase of approximately 29%, indicating a resurgence in market enthusiasm for tech and consumer companies [3] Group 3: Competitive Landscape - If successful, Watsons will compete with other retail entities such as Sa Sa International in Hong Kong and THG listed in London [4] - The global beauty retail market is currently under pressure, necessitating Watsons to demonstrate the effectiveness of its transformation strategy [4] - The specifics of the dual listing timeline and equity structure remain undisclosed, with the market closely monitoring further developments [4]

Core Viewpoint - The CEO of Li Ning, Qian Wei, acknowledged the pressure from reduced offline foot traffic and the increasing competition within the sportswear industry, while expressing confidence in consumer interest in sports remaining strong [1] Group 1: Company Performance and Strategy - Li Ning has prepared for greater challenges in the second half of the year, indicating a proactive approach to market conditions [1] - The company has established a dynamic inventory management system, alleviating concerns about inventory pressure [1] - Li Ning aims to maintain a core gross profit margin target of 50% while optimizing its offline channel structure [1] Group 2: Market Trends - The trend of consumer segmentation is noted, with an emphasis on the evolving preferences within the sportswear market [1] - The company has completed initial construction of Super Outlets and Outlet Mega Stores, indicating a strategic expansion in retail presence [1]